7hp349
Small moleculeexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Oct 31, 2020 (NCT04508179)
Timeline
2020s
- Jan 1, 2020
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
- Anaplastic Lymphoma Kinase · Phase 1/Phase 2
- Carcinoma, Hepatocellular · Phase 1/Phase 2
- Carcinoma, Non-Small-Cell Lung · Phase 1/Phase 2
- Carcinoma, Renal Cell · Phase 1/Phase 2
- Colorectal Neoplasms · Phase 1/Phase 2
- DNA Mismatch Repair · Phase 1/Phase 2
- Kidney Neoplasms · Phase 1/Phase 2
- Liver Neoplasms · Phase 1/Phase 2
- Melanoma · Phase 1/Phase 2
- Mesothelioma · Phase 1/Phase 2
- Microsatellite Instability · Phase 1/Phase 2
- Neoplasm Metastasis · Phase 1/Phase 2
- Neoplasms · Phase 1/Phase 2
- Skin Neoplasms · Phase 1/Phase 2
Mechanism of action
- Fibronectin receptor betaACTIVATOR
ITGB1 activator
ITGAL activator
Chemistry & pharmacology
Loading structure…
SMILES
O=C(OCCOCCOCCOC(=O)N(Cc1cccs1)Cc1cccs1)N(Cc1cccs1)Cc1cccs1- Mol. weight
- 620.84 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL5314453 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06362369 | Phase 1/Phase 2 (Phase 2) | Aug 23, 2024 | 7 Hills Pharma, LLC |
| NCT04508179 | Phase 1 | Oct 31, 2020 | 7 Hills Pharma, LLC, Frontage Laboratories, Inc. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| 7 Hills Pharma, LLC | For profit | 2 | 2 | 2 | 2020 |
| Frontage Laboratories, Inc. | For profit | 1 | 0 | 1 | 2020 |
2 organizations
Page 1 / 1